Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Saturday, September 22, 2012

Switching to tenofovir suppresses hepatitis B in HIV/HBV co-infected people

People with HIV and hepatitis B virus (HBV) co-infection, who substituted tenofovir (Viread) for zidovudine (Retrovir) or abacavir (Ziagen) in their antiretroviral regimen, saw a reduction in hepatitis B viral load despite HBV being resistant to lamivudine (Epivir), according to a poster presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.

Some antiretroviral drugs, including tenofovir and lamivudine, are also active against hepatitis B virus. European and US treatment guidelines recommend that people with HIV/HBV co-infection should include at least one of these drugs in their antiretroviral regimen. Hepatitis B virus rapidly develops resistance to lamivudine, however, which may compromise its effectiveness.

Read more...

No comments:

Post a Comment